HLB Pharmaceutical Co., Ltd (047920.KQ)
KRW 18520.0
(1.26%)
KRW 18520.0
(1.26%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 135.95 Billion | 107.48 Billion | 62.85 Billion | 40.57 Billion | 36.09 Billion | 20.54 Billion |
| Cost of Revenue | 52.96 Billion | 43.82 Billion | 27.92 Billion | 18.71 Billion | 18.63 Billion | 16.31 Billion |
| Gross Profit | 82.98 Billion | 63.65 Billion | 34.92 Billion | 21.86 Billion | 17.46 Billion | 4.23 Billion |
| Operating Expenses | 102.52 Billion | 70.59 Billion | 34.68 Billion | 21.21 Billion | 16.46 Billion | 10.34 Billion |
| Selling, General and Administrative Expenses | 98.85 Billion | 65.98 Billion | 31.23 Billion | 18.96 Billion | 13.79 Billion | 7.29 Billion |
| Research and Development Expenses | 2.3 Billion | 4.25 Billion | 3.1 Billion | 1.99 Billion | 2.46 Billion | 2.79 Billion |
| Other Expenses | 1.36 Billion | -356.75 Million | -347 Million | -254.69 Million | -197.98 Million | -246.97 Million |
| Cost and Expenses | 155.49 Billion | 114.42 Billion | 62.61 Billion | 39.92 Billion | 35.09 Billion | 26.65 Billion |
| Operating Income | -19.54 Billion | -6.94 Billion | 236.89 Million | 646.1 Million | 1 Billion | -6.11 Billion |
| Interest Expense | 11.76 Billion | 5.02 Billion | 15.87 Billion | 12.65 Billion | 1.19 Billion | 859.58 Million |
| Income Tax Expense | 576.06 Million | 824.93 Million | 408.14 Million | -17.64 Billion | -595.68 Million | 1.34 Billion |
| Earnings before Tax | -16.23 Billion | -5.78 Billion | -11.38 Billion | -92.48 Billion | -123.03 Million | -5.71 Billion |
| Net Income | -19.42 Billion | -11.77 Billion | -13.22 Billion | -74.84 Billion | 472.65 Million | -7.05 Billion |
| Earnings Per Share Basic | -666.05 | -431.02 | -573.24 | -4747.10 | 34.13 | -521.49 |
| Earnings Per Share Diluted | -666.05 | -431.02 | -573.24 | -4747.10 | 34.13 | -521.49 |
| Weighted Average Shares Outstanding | 29.16 Million | 27.32 Million | 23.07 Million | 15.76 Million | 13.84 Million | 13.53 Million |
| Weighted Average Shares Outstanding (Diluted) | 29.16 Million | 27.32 Million | 23.07 Million | 15.76 Million | 13.84 Million | 13.53 Million |
| Gross Margin | 0.61 | 0.59 | 0.56 | 0.54 | 0.48 | 0.21 |
| EBIT Margin | 0.00 | -0.02 | 0.06 | 0.07 | 0.06 | -0.24 |
| Profit Margin | -0.14 | -0.11 | -0.21 | -1.84 | 0.01 | -0.34 |
| EBITDA | 581.09 Million | -1.39 Billion | 8.28 Billion | -77.76 Billion | 2.13 Billion | -3.71 Billion |
| Earnings Before Tax Margin | -0.14 | -0.06 | 0.00 | 0.02 | 0.03 | -0.30 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 35.77 Billion | 33.45 Billion | 33.71 Billion | 135.95 Billion | 34.63 Billion | 35.2 Billion |
| Cost of Revenue | 14.01 Billion | 12.02 Billion | 14.27 Billion | 54.44 Billion | 14.29 Billion | 12.92 Billion |
| Gross Profit | 21.75 Billion | 21.42 Billion | 19.44 Billion | 81.5 Billion | 20.34 Billion | 22.27 Billion |
| Operating Expenses | 21.2 Billion | 20.21 Billion | 23.72 Billion | 101.82 Billion | 27.94 Billion | 31.07 Billion |
| Selling, General and Administrative Expenses | 20.48 Billion | 19.43 Billion | 22.97 Billion | - | 27.18 Billion | 30.6 Billion |
| Research and Development Expenses | 644.2 Million | 632.67 Million | 674.58 Million | - | 682.49 Million | 382.26 Million |
| Other Expenses | -68.27 Million | -141.29 Million | -78.12 Million | -377.8 Million | -84.97 Million | -85.98 Million |
| Cost and Expenses | 35.21 Billion | 32.23 Billion | 37.99 Billion | 156.27 Billion | 42.24 Billion | 43.99 Billion |
| Operating Income | 554.32 Million | 1.21 Billion | -4.28 Billion | -20.32 Billion | -7.6 Billion | -8.79 Billion |
| Interest Expense | 177.33 Million | 74.49 Million | 186.73 Million | 11.76 Billion | 2.69 Billion | 8.71 Billion |
| Income Tax Expense | 11.46 Million | 6.23 Million | -228.53 Million | 576.06 Million | 1.06 Billion | -261.11 Million |
| Earnings before Tax | 667.28 Million | -1.36 Billion | 4.65 Billion | -16.23 Billion | -5.93 Billion | -15.66 Billion |
| Net Income | 496.29 Million | -1.6 Billion | 5.18 Billion | -19.42 Billion | -7.64 Billion | -17.68 Billion |
| Earnings Per Share Basic | 15.62 | -51.22 | 171.17 | - | -256.93 | -613.84 |
| Earnings Per Share Diluted | 10.17 | -51.22 | 171.17 | - | -256.93 | -613.84 |
| Weighted Average Shares Outstanding | 31.76 Million | 31.41 Million | 30.31 Million | 29.16 Million | 29.74 Million | 28.8 Million |
| Weighted Average Shares Outstanding (Diluted) | 32.07 Million | 31.41 Million | 30.31 Million | 29.16 Million | 29.74 Million | 28.8 Million |
| Gross Margin | 0.61 | 0.64 | 0.58 | 0.60 | 0.59 | 0.63 |
| EBIT Margin | 0.05 | 0.08 | -0.09 | - | -0.18 | -0.21 |
| Profit Margin | 0.01 | -0.05 | 0.15 | -0.14 | -0.22 | -0.50 |
| EBITDA | 1.84 Billion | 2.52 Billion | -2.96 Billion | - | -6.29 Billion | -7.53 Billion |
| Earnings Before Tax Margin | 0.02 | 0.04 | -0.13 | -0.15 | -0.22 | -0.25 |
TRR
GENCON
TMVWY
PICCADIL
AWLCF
2155